ArticleCurrent cancer drug targets2025

Phase I Clinical Trial of CD19 CAR-T Cells Expressing CXCR5 Protein for the Treatment of Relapsed or Refractory B-cell Lymphoma.

Jiaxi Wang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.